收藏切换
The effect of rituximab adjuvant GDP regimen on non-Hodgkin lymphoma and its influence on TK-1, FASL and PDGF-BB
收藏切换
Junqin JI, Zhiqiang GUO, Ning XU*, Yijing ZHAO, Liling YIN, Jinling LIU
World Clinical Drug | 2025, 46(12) : 1263 - 1269
Less
收藏切换
World Clinical Drug | 2025, 46(12): 1263-1269
• Article •
The effect of rituximab adjuvant GDP regimen on non-Hodgkin lymphoma and its influence on TK-1, FASL and PDGF-BB
Full
Junqin JI, Zhiqiang GUO, Ning XU*, Yijing ZHAO, Liling YIN, Jinling LIU
Affiliations
  • Department of Oncology, Fenyang Hospital of Shanxi Province/Fenyang Hospital Affiliated to Shanxi Medical University, Fenyang 032200, Shanxi Province, China
Published: 2025-12-10 doi: 10.13683/j.wph.2025.12.010
Outline
收藏切换
Objective

To explore the efficacy of rituximab as an adjuvant to GDP in the treatment of non-Hodgkin lymphoma(NHL) and its effect on thymidine kinase(TK)-1, recombinant factor related apoptosis ligand(FASL) and platelet-derived growth factor(PDGF)-BB.

Methods

A total of 210 NHL patients who were treated in our hospital from September 2021 to September 2024 were selected and randomly divided into the observation group and the control group,with 105 cases in each group. The control group was given the GDP regimen, while the observation group was added with rituximab. The clinical efficacy, TK-1, FASL, PDGF-BB, changes of peripheral blood T lymphocyte subsets, cluster of differentiation(CD)8+, CD4+ and CD3+ of the two groups were compared to evaluate the quality of life and occurrence of adverse reactions of the patients.

Results

A total of 103 cases in the observation group and 101 cases in the control group completed the study. After treatment, the disease control rate of the observation group was higher than that of the control group(72.82% vs. 58.42%, P<0.05). The levels of TK-1, FASL and PDGF-BB in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). The CD8+ level in both groups was lower than that before treatment(P<0.05), and the level in the observation group was lower than that in the control group(P<0.05). The levels of CD4+ and CD3+ were increased before treatment, and the levels in the observation group were higher than those in the control group(P<0.05). The scores of physical function,emotional function, social function, cognitive function and role function of the two groups of patients were significantly higher, and the observation group was higher than the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups of patients(P>0.05).

Conclusion

Among NHL patients, the rituximab adjuvant GDP regimen has a better therapeutic effect and can effectively improve the levels of TK-1, FASL and PDGF-BB.

rituximab  /  chemotherapy plan  /  non-Hodgkin lymphoma  /  thymidine kinase-1  /  apoptosis-related factor ligand  /  platelet-derived growth factor-BB
冀俊琴, 郭志强, 许宁, 赵一静, 殷丽玲, 刘金玲. 利妥昔单抗辅助GDP方案对非霍奇金淋巴瘤的效果及对TK-1、FASL及PDGF-BB的影响. 世界临床药物, 2025 , 46 (12) : 1263 -1269 . DOI: 10.13683/j.wph.2025.12.010
Junqin JI, Zhiqiang GUO, Ning XU, Yijing ZHAO, Liling YIN, Jinling LIU. The effect of rituximab adjuvant GDP regimen on non-Hodgkin lymphoma and its influence on TK-1, FASL and PDGF-BB[J]. World Clinical Drug, 2025 , 46 (12) : 1263 -1269 . DOI: 10.13683/j.wph.2025.12.010
Year 2025 volume 46 Issue 12
42
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.12.010
  • Receive Date:2025-05-28
  • Online Date:2026-11-09
  • Published:2025-12-10
Article Data
Affiliations
History
  • Received:2025-05-28
Affiliations
    Department of Oncology, Fenyang Hospital of Shanxi Province/Fenyang Hospital Affiliated to Shanxi Medical University, Fenyang 032200, Shanxi Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.12.010
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT